Left ventricular hypertrophy in patients with chronic renal failure treated by hemodialysis;Przerost lewej komory serca u chorych na przewlekła̧ niewydolność nerek leczonych hemodializa̧

Polskie Archiwum Medycyny Wewnetrznej

Volumn 107, Issue 6, 2002, Pages 539-546

  Wanic Kossowska, Maria ^b   Lehmann, Piotr ^b   Czekalski, Stanisław ^a  

^a Klinika Nefrologii AM w Poznaniu   (Poland)

^b Pozna Nowe Miasto   (Poland)

Author keywords

Anaemia; Hyperparathyroidism; Left ventricular hypertrophy; Malnutrition; Risk of sudden death

Indexed keywords

CREATININE; ELECTROLYTE; HEMOGLOBIN; PARATHYROID HORMONE; PLASMA PROTEIN; SERUM ALBUMIN; UREA;

ADULT; ARTICLE; BLOOD; BODY MASS; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HUMAN; MALE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ADULT; BLOOD PROTEINS; BODY MASS INDEX; CASE-CONTROL STUDIES; COHORT STUDIES; CREATININE; ECHOCARDIOGRAPHY; ELECTROLYTES; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; RISK FACTORS; SERUM ALBUMIN; UREA;

EID: 0036616798     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Vaziri S.M., Larson G.M., Banjamin E.N., Levy D.: Echocardiographic predictors of non-rheumatic atrial fibrillation: the Framingam Heart Study. Circulation, 1994, 89, 724.
2. Karmel W.B., Levy D., Cupples L.A.: Left ventricular hypertrophy and risk of cardiac failure. Insights from the Framingham Study. J. Cardiovasc. Pharmacol., 1987, 10 (suppl. 6), 135.
3. Kunz K., Dimitrov Y., Muller S.: Uremic cardiomyopathy. Nephrol. Dial. Transplant., 1998, 13, (suppl. 4), 39.
4. Fujimoto S., Kagoshima T., Hashimoto T., Nakajima T.: Left ventricular diastolic function in patients on maintenance hemodialysis: comparison with hypertensive heart disease and hyperthrophic cardiomiopathy. Clin. Nephrol., 1994, 42, 2, 109.
5. Devereux R.B., Alonso D.R., Lutas E.M.: Echocardiographic assessement of left ventricular hypertrophy, comparison to necropsy findings. Am. J. Cardiol., 1986, 57, 450:
6. Armitage P.: Metody statystyczne w badaniach medycznych. PZWL, Warszawa, 1978.
7. Ganau A., Devereux R.B., Roman M.J.: Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J.Am. Coll. Cardiol., 1992, 19, 15.
8. Tucker B., Fabbian F., Giles M., Thuraisingham R., Raine A.E.G.: Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol. Dial. Transplant., 1997, 12, 724.
9. Wanic-Kossowska M., Lehman P., Czekalski S.: 24-godzinne monitorowanie cisnienia tȩtniczego a przerost lewej komory serca u chorych na przewlekła̧ niewydolność nerek (p.n.n.) leczonych hemodializa̧. (HD). Praca wydana do druku w Pol. Arch. Med. Wewn., 2001.
10. Pasierski T., Grodzicki T.: Nadciśnieniowa choroba serca. Medycyna Praktyczna, Krakow 1999, 17.
11. Duprez D.A., Bawvens F.R., DeBuyzere F.R.: Influence of atrial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am. J. Cardiol., 1993, 71, 17.
12. Korteleinen M.L., Sarkioja T.: Extent and composition of coronary lesions and degree of cardiac hypertrophy in relation to abdominal fatness in men under 40 years of age. Arterioscl. Thromb. Vasc. Biol., 1997, 17, 574.
13. Weber K.T., Sun Y., Guarda E.: Structural remodelling in hypertensive heart disease and the role of the hormones. Hypertension, 1994, 23, 869.
14. Katz A.: Cardiomiopathy of overload. A major determinant of prognosis in congestive heart disease. New Engl. J. Med., 1990, 322, 100.
15. Herman Z.S.: Mechanizmy działania IKA. Leki hamuja̧ce enzym przeksztalcaja̧cy angiotensynȩ. Działanie i zastosowanie kliniczne. Pod redakcja̧ prof. dr hab. H. Adamskiej-Dyniewskiej. Towarzystwo Terapii Monitorowanej, Łódź, 1997.
16. Sinim A., Nestler M., Hoppe V.: PDGF-AA, a potent mitogen for cardiac fibroblasts from adults rats. J. Moll. Cell. Cardiol., 1997, 29, 357.
17. Marban E., Koretsune Y: Cell calcium, oncogenes and hypertrophy. Hypertension, 1990, 15, 652.
18. Smogorzewski M., Massry S.G.: Uremic cardiomiopathy. Role of parathyroid hormone. Kidney Int., 1997, 52 (suppl. 62), 12.
19. Amman K., Ritz E., Wiest G., Klaus G., Mall G.: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J. Am. Soc. Nephrol., 1994, 4, 1814.
20. Ritz E., Vallance P., Nowicki M.: The effect of malnutrition on cardiovascular mortality in dialysis patients: is L-arginine the answer? Nephrol. Dial. Transplant., 1994, 9, 129.
21. Brilla O.G., Zlion G., Weber K.T.: Aldosterone-mediated stimulation of collagen synthesis in cultured cardiac fibroblasts. J. Hypertension, 1992, 10, (suppl. 4), 537.
22. Morishita R., Gibbons G.H., Ellison K.E.: Evidence for direct local effect of angiotensin in vascular hypertrophy. J. Clin. Invest., 1994, 94, 978.
23. Locatelli F., Marcelu D., Conte F., D'Amico M.: Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol. Dial. Transplant., 2000, 15, (suppl.5), 69.
24. Okano K., Wu S., Huang X.: Parathyroid hormone (PTH)/PTH-related protein (PTHrp) receptor and its mesenger ribonucleic acid in rat aortic vascular smooth muscle cells and UMR osteoblastlike cells: cellc-specific regulation by angiotensin-II and PTHrp. Endocrinology, 1994, 135, 1093.
25. Pirola C.J., Wang H., Kamyar A.: Angiotensin-II regulates parathyroid hormone related protein expression in cultured rat aortic smooth muscle cells through transcriptional and post-transcriptional mechanisms. J. Biol. Chem., 1993, 268, 268.
26. Sułowicz W., Pietrzyk J.A.: Kliniczne znaczenie monitorowania adekwatności dializy. Dializoterapia w codziennej praktyce. Pod redakcja̧ prof. B. Rutkowskiego, MAKmed, Gdańsk, 1996, 139,.
27. Himmelfarb J., Holbrook D., Mc Mongole E., Robinson R.: Kt/V, nutritional parameters, serum cortisol and insulin growth factor-1 levels and patient outcome in hemodialysis. Am. J. Kidney Dis., 1994, 24, 3, 473.
28. Amann K., Gross M.L., London G.M., Ritz E.: Hyperphosphatemia - a silent killper of patients with renal failure.
29. Foley R.N., Parfrey P.S., Kent G.M. Harnett J.D.: Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int., 1998, 54, 1720.
30. Zehnder C., Zuber M., Sulzer M.: Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialysed patients. Nephron, 1992, 61, 21.
31. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M.: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis., 1996, 28, 1, 53.
32. Schunkert H., Hense H.W.: A heart price to pay for anemia. Nephrol. Dial. Transplant., 2001, 16, 445
33. Koren M.L, Devereux R.B., Casale P.N.: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Int. Med., 1991, 67, 295.
34. Greaves S.C., Gamble G.D., Collins J.F., Whalley G.A.: Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am. J. Kidney Dis., 1994, 24, 5, 768.
35. Levy D., Garrison R.J., Savqge D.D., Kamel W.B.: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl. J. Med., 1990, 322, 1561.